Two studies were performed to assess the entero-insular axis in simple obesity and the possible effect of variations in the level of circulating non-esterified fatty acids (NEFA) on one of the components of the entero-insular axis, glucagon-like peptide-1 [(7-36) amide]. In the first study, we compared the entero-pancreatic hormone response to oral carbohydrate in obese and lean women. Obese subjects demonstrated hyperinsulinaemia and impaired glucose tolerance but this was not associated with an increased secretion of either glucose-dependent insulinotropic polypeptide or glucagon-like peptide-1 (GLP-1). These findings therefore provide no support for the hypothesis that overactivity of the entero-insular axis contributes to the hyperinsulinaemia seen in obesity. Indeed, the plasma GLP-1 response to carbohydrate was markedly attenuated in obese subjects, confirming previous observations. In the second study, in which carbohydratestimulated GLP-1 responses were again evaluated in obese and lean women, circulating NEFA levels were modulated using either heparin (to increase serum NEFA) or acipimox (to reduce serum NEFA). Treatment with acipimox resulted in complete suppression of NEFA levels and in a markedly higher GLP-1 response than the response to carbohydrate alone or to carbohydrate plus heparin. We suggest that higher fasting and postprandial NEFA levels in obesity may tonically inhibit nutrient-mediated GLP-1 secretion, and that this results in attenuation of the GLP-1 response to carbohydrate. However, although serum NEFA levels post-acipimox were similarly suppressed in both lean and obese subjects, the GLP-1 response was again significantly lower in obese subjects, suggesting the possibility of an intrinsic defect of GLP-1 secretion in obesity. The reduction of GLP-1 levels in obesity may be important both in relation to its insulinotropic effect and to its postulated role as a satiety factor.
INTRODUCTION
The two major hormones of the entero-insular axis are now believed to be glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1] . Both act as incretins and have a synergistic effect in increasing the insulin response to oral feeding in the presence of hyperglycaemia. In addition to its insulinotropic and glucagonostatic [2] action, postprandial secretion of GLP-1 may have important metabolic and endocrine effects. It has been shown to increase peripheral glucose disposal, and it has been suggested that this may be a direct effect, not mediated by the action of GLP-1 on pancreatic hormone secretion [3] . GLP-1 receptors are widely distributed in the body and have been found in tissues as diverse as liver, skeletal muscle, pancreatic islets, adipocytes, brain, stomach and lungs. There is evidence that adipose tissue fatty acid metabolism may also be influenced by GLP-1 although data are confusing ; studies which show that GLP-1 may increase fatty acid synthesis in adipose tissue explants [4] and decrease levels of circulating non-esterified fatty acids (NEFA) after systemic administration [2] appear to conflict with the finding that it may increase lipolysis in isolated adipocytes [5] .
Recent interest has centred on the fact that GLP-1 may play a role in the control of both gastric emptying and satiety. When administered intracerebrally, GLP-1 has been shown to increase satiety and to reduce food intake [6, 7] . In addition, both endogenously secreted (ileal) and exogenously administered GLP-1 have been shown to inhibit gastric emptying and to reduce food and water intake [8] [9] [10] . GLP-1 receptors have been described in the pylorus of the stomach, consistent with a direct effect on gastric emptying. The inhibitory effect of GLP-1 on gastric acid secretion and gastric emptying is abolished by vagotomy [11] [12] [13] ; this suggests that at least some of the effects of circulating GLP-1 may be centrally mediated. In view of the fact that gastric distension may be an important factor that curtails eating [14, 15] , factors that control gastric emptying -including postprandial GLP-1 secretion -may be important determinants of eating behaviour and therefore of potential importance in both the development of and the perpetuation of obesity.
Preliminary studies have shown that there may be marked differences between lean and obese subjects in terms of their GLP-1 response to carbohydrate stimulation, with significantly lower levels in obesity [16] . The results of this earlier study also indicated that GLP-1 secretion may be inhibited by circulating NEFA. It is well recognized that obesity is characterized by higher fasting plasma NEFA concentrations and impaired postprandial suppression of NEFA [17] . It is therefore possible that higher plasma NEFA concentrations in the obese may account for the reduction of postprandial GLP-1 secretion described previously [16] .
The aims of the present studies were to confirm the observation that postprandial GLP-1 release may be reduced in obesity (Study 1), and to clarify the effect of circulating NEFA on GLP-1 secretion by measuring GLP-1 responses in the presence of various levels of plasma NEFA (Study 2). Two methods were used to modify NEFA levels : intravenous heparin (which releases lipoprotein lipase from the capillary endothelium, resulting in increased hydrolysis of circulating lipoprotein triacylglycerols) was used to raise NEFA levels, and acipimox (an analogue of nicotinic acid which inhibits adipose tissue lipolysis) was used to lower plasma NEFA levels. Previous investigators have employed similar strategies to modulate circulating NEFA concentrations [18, 19] .
MATERIALS AND METHODS

Study protocol
The study protocols were approved by the Epsom General Hospital Medical Ethics Committee. Written consent was obtained from all participants.
Subjects
In Study 1, 13 obese (body mass index 30 kg\m#) and 13 healthy age-matched lean (20-25 kg\m#) women were recruited. For Study 2, seven obese (body mass index 30 kg\m#) and seven healthy age-matched lean (20-25 kg\m#) women were recruited. All obese subjects were attending the metabolic clinic. All subjects were non-smokers and none was taking any medication.
Experimental procedures
Study 1
All subjects attended for study on a single occasion after an overnight fast of 12-14 h. All subjects had abstained from alcohol for 24 h before the study. Studies were carried out with the subjects seated and at rest. An indwelling cannula was sited in a forearm vein and maintained patent with saline. Venous blood samples were collected via the cannula before (k15 and 0 min) and 15, 30, 45, 60, 75, 90, 105 and 120 min after the administration of 100 g of carbohydrate (155 ml of Hycal4, SmithKline Beecham, Herts, U.K., made up to a volume of 300 ml with water).
Study 2
All subjects attended for study on three occasions separated by at least a week after an overnight fast. They were given, in random order, either Hycal alone (equivalent to 100 g of carbohydrate), Hycal with heparin or Hycal with acipimox. Heparin was given as a bolus of 10 000 units of heparin intravenously at time 0 (i.e. at the same time as the Hycal). Acipimox (500 mg) was given 2 h before Hycal. All subjects were also given 75 mg of oral acetylsalicylic acid 30 min before acipimox administration to prevent the cutaneous side effects of acipimox. The procedure and timing of blood samples was as in Study 1.
Blood samples
Samples were taken into heparinized tubes containing aprotinin (1000 kallikrein-inhibitory units\ml) for insulin, GIP and GLP-1 ; into fluoride\oxalate tubes for glucose ; and into plain glass bottles for NEFA and triacylglycerol measurements (no specific inhibitors of lipolysis were used). NEFA were measured in Study 2 only. Heparinized and fluoride\oxalate samples were centrifuged immediately at 1200 g for 5 min ; plasma was separated and frozen at k20 mC in aliquots until analysis. Blood collected for NEFA and triacylglycerol analysis was centrifuged at 1200 g (for 5 min) 30 min after collection, and serum was separated and stored in aliquots at k20 mC until analysis.
Laboratory assays
Samples from subject pairs were assayed in the same analytical run for both studies. Glucose, NEFA and triacylglycerols were measured on an Olympus4 560 analyser. Glucose was measured by a glucose oxidase method. Triacylglycerols and NEFA, using Randox4 kits, were also assayed by enzymic methods. All these measurements had an inter-assay coefficient of variation of 5%.
Insulin, GIP and GLP-1 were measured using inhouse radioimmunoassay methods described in detail elsewhere [20] [21] [22] . The inter-assay coefficients of variation for hormone measurements were : for insulin, 25.9, 12.3 and 6.8 % at 62.2, 266 and 448 pmol\l respectively ; for GIP, 8.6 and 8.9 % at 300 and 497 pmol\l respectively ; and for GLP-1, 17.8 and 15.4 % at 22.6 and 64.5 pmol\l respectively.
Statistical analysis
Statistical analysis of the results was performed using the Instat statistical package. Total and incremental integrated responses were calculated using the trapezoidal rule. Repeated measures ANOVA was used to assess significant differences in the integrated responses for each analyte between obese and lean groups as well as between the different limbs of the study. For Study 1, both areas under the curve (AUC) and individual time points for the lean and obese groups were compared using paired Student's t-test. Comparisons between the three limbs of Study 2 were made by one-way ANOVA, and any significant differences identified using the Bonferroni correction for multiple comparisons. Values of P 0.05 were considered significant.
RESULTS
Study 1
Fasting levels and responses to Hycal of plasma glucose, triacylglycerol, insulin, GIP and GLP-1 in lean and obese subjects are shown in Figures 1 and 2 and in Tables 1  and 2 .
Fasting glucose levels were similar in the two groups but mean fasting triacylglycerol and insulin levels were higher in the obese group (P 0.01 and P 0.001 respectively). Glucose and insulin levels rose promptly to peak at 30 min in the lean subjects and at 60 min in the obese subjects. In lean subjects, glucose and insulin levels returned to near baseline values by 120 min, but in the obese group both glucose and insulin levels remained elevated at 120 min. The glucose and insulin responses to Hycal were greater in obese than in lean subjects ; differences between total and incremental AUC for glucose were P 0.003 and P 0.002 respectively, and for insulin P 0.0001 and P 0.0001 respectively. GIP responses were similar in both groups. However, the overall GLP-1 response was significantly higher in the lean group (total and incremental AUC, lean compared with obese, P 0.03 and P 0.05 respectively). The GLP-1 response was prompt in both groups, reaching a peak at 30 min. In the lean group GLP-1 responses were sustained throughout the study period, and although there was some decline after 90 min, the level remained above baseline at 120 min. In the obese group, however, the GLP-1 response was poorly sustained, returning to basal levels by 90 min.
Study 2
There were a number of quantitative differences between lean and obese subjects in both fasting and post-Hycal levels of NEFA, GLP-1 and triacylglycerols ; these are discussed below and shown in Tables 3 and 4 . However, since the metabolite and hormone responses were qualitatively similar in obese and lean groups, they have been combined into a single group for the sake of clarity. These responses are illustrated in Figures 3 and 4 .
Fasting serum NEFA levels were higher in obese than in lean subjects (P 0.05) ; they were completely suppressed by acipimox in both groups. After Hycal alone, NEFA levels fell to reach a nadir at 30 min in lean subjects and 60 min in obese subjects, and remained suppressed until the end of the study (120 min). There was less of a decrease in NEFA levels in obese subjects after Hycal (greater total and incremental AUC, P 0.01 for both). NEFA levels rose promptly after heparin to peak at 15 min before decreasing to reach baseline levels by 75 min ; this response (incremental AUC) was greater in obese subjects (P 0.05), and greater in all subjects than after Hycal alone or Hycal plus acipimox (P 0.01 for both). Fasting serum triacylglycerols were higher in obese than in lean subjects (P 0.05). After heparin administration, there was a steady fall in triacylglycerol levels reaching a nadir at 60 min in both lean and obese subjects. The magnitude of the fall was similar in both groups.
GLP-1 rose promptly to peak at between 30 and 45 min both in the lean and obese groups after Hycal. The response was enhanced in the lean group after acipimox and attenuated after heparin in the lean and obese groups. When the results for both groups were combined (see Figure 4 and Table 4 ), the GLP-1 response to Hycal plus acipimox was significantly greater than the response to Hycal alone (integrated AUC ; P 0.01) as well as heparin plus Hycal (total and integrated AUC ; P 0.01). The response to all three challenges was more sustained in lean than in obese subjects ( Figure 4) ; in lean subjects, GLP-1 levels remained well above baseline at 120 min, whereas in the obese group, there was a marked decline towards fasting values after 30-45 min.
DISCUSSION
It has been suggested that overactivity of the enteroinsular axis may contribute to the hyperinsulinaemia of obesity. Study 1 was undertaken to determine whether insulin, GIP and GLP-1 responses to nutrients were excessive in obese subjects. As in numerous previous studies, the obese group was found to exhibit the combination of carbohydrate intolerance and hyperinsulinaemia, characteristic of the insulin resistance that is commonly observed in association with obesity. However, there was no evidence for hypersecretion of the insulinotropic gastrointestinal hormones, GIP or GLP-1. With respect to GIP, these findings are similar to those of some studies [23] but in contrast to others [24] . The reason for these discrepancies is unclear but, overall, there is little evidence that GIP plays a role in the hyperinsulinaemia of obesity. With respect to GLP-1, however, we have confirmed our initial observation [16] that there is marked attenuation of the GLP-1 response to carbohydrate in obesity. It is also of interest that an earlier study by Holst et al. [25] showed reduced L-cell secretion in human obesity through documentation of markedly impaired glicentin secretion ; the peptides secreted by L-cells include GLP-1 and GLP-2 as well as glicentin. A more recent study has also confirmed a marked reduction in carbohydrate-mediated GLP-1 secretion in obesity [26] . The mechanism for this impaired secretion in obesity is unclear, but the results of Study 2 indicate that it may be due to defective postprandial suppression of NEFA in obesity. The finding that both fasting and post-carbohydrate NEFA levels were higher in obese subjects confirms previous studies [17] . Although we were successful in achieving manipulation of NEFA levels using heparin and acipimox in both lean and obese subjects, quantitative differences in postprandial NEFA levels in the two groups were evident : the higher fasting NEFA levels in the obese indicate less complete suppression of lipolysis, while the 2-fold higher NEFA levels in the obese after heparin presumably represent the larger pool of triacylglycerol available for hydrolysis.
A reciprocal relationship between GLP-1 and NEFA levels was seen in Study 2 which both confirms and extends our earlier finding [16] , with a reduction in plasma GLP-1 associated with the rise in NEFA levels after heparin, and an increase in plasma GLP-1 associated with suppression of NEFA levels by acipimox. These findings suggest that physiological fluctuations in plasma NEFA levels may influence GLP-1 secretion. The stimulus for the early postprandial release of GLP-1 secretion is not clearly understood. Studies in animals have indicated a possible role for GIP and\or the parasympathetic system in release of GLP-1 from the ileum in response to the presence of food in the duodenum and jejunum [27, 28] , but no such mechanism has been demonstrated in man [1] . We suggest that the fall in plasma NEFA levels after ingestion of food may be an important mechanism by which GLP-1 release is either stimulated or enhanced and that failure of NEFA suppression may be partly responsible for the impaired GLP-1 secretion seen in obesity. Fat-rich mixed meals, especially in obese subjects, lead to higher NEFA circulating levels and reduced suppression of NEFA postprandial concentrations [29] ; energy intake is greater when food is consumed as fat rather than as carbohydrate [30] . The inhibition of GLP-1 postprandial secretion by NEFA during high-fat mixed meals is consistent with reduced satiety in these circumstances and greater food intake leading to obesity. Flint et al. [31] have recently shown that GLP-1 administration reduces food intake in human subjects.
There remains the possibility, however, that there may be an intrinsic defect in GLP-1 secretion in obesity which both antedates and contributes to the development of obesity. Obese subjects showed significantly attenuated GLP-1 responses in Study 1 ; although GLP-1 responses were generally lower in the obese than in the lean subjects even in Study 2, this difference became significant only after acipimox. In Study 2, postprandial GLP-1 responses were significantly attenuated in the obese group after acipimox plus Hycal despite reduction of serum NEFA to a similar extent in both groups. This provides some support for the suggestion of an underlying intrinsic deficiency in postprandial GLP-1 secretion in obesity although further studies on a larger number of subjects before and after weight loss are required to establish this convincingly.
The combination of evidence from other studies showing a reduction of NEFA by GLP-1 administration [2, 32] with the demonstration of regulation of GLP-1 Non-esterified fatty acids : effect on glucagon-like peptide-1 Scheme 1 Suggested interaction between GLP-1 and NEFA j denotes stimulation ; k denotes inhibition.
secretion by the level of NEFA in plasma in the present study suggests the existence of a bidirectional relationship between GLP-1 and NEFA, with the potential of a selfreinforcing cycle (Scheme 1). A primary deficiency of GLP-1 may predispose to higher plasma NEFA levels, or alternatively, a primary increase in NEFA may suppress GLP-1 secretion. There is evidence from both animal studies [33] and clinical experience that obesity tends to be self-perpetuating. This leads to difficulties in the treatment of human obesity such that, even if successful, there is an inevitable tendency to regain any weight lost. We speculate that a ' NEFA-GLP-1 ' cycle, through its effects on gastric emptying and satiety, could play a part in the perpetuation or resumption of the obese state. It is also possible that there is an intrinsic defect in GLP-1 secretion that predisposes to the development of obesity ; the persistently reduced GLP-1 responses in our obese group despite NEFA suppression post-acipimox suggests that this may be the case.
The relationship between fatty acid and glucose metabolism was described by Randle et al. [34] more than 30 years ago ; increased glucose-fatty acid cycle activity results in a reduction in glucose tolerance, glucose disposal, glucose oxidation and insulin sensitivity in addition to increased hepatic glucose production and lipid oxidation [35, 36] . Administration of GLP-1 has been shown to increase glucose disposal, glucose oxidation and glucose storage, and to improve glucose tolerance and insulin sensitivity while reducing hepatic glucose production. It is tempting to speculate that the reduction in plasma NEFA levels seen in response to GLP-1 administration may reflect a decrease in fatty acid oxidation, and that GLP-1 deficiency may result in a decrease in glucose-fatty acid cycle activity. GLP-1 may thus be acting as a humoral component of the glucosefatty acid cycle.
In conclusion, in this study we describe for the first time a relationship between circulating NEFA and GLP-1 of potential physiological significance influencing energy metabolism and food intake, indicating a link between the organ of storage (adipose tissue) and the organ of digestion and absorption of food (small intestine).
